Exelixis Building A Pipeline Out Of A Product, Unveils Cabozantinib Activity Across Tumor Types At ASCO

Exelixis Inc. is set to file the first NDA for its dual MET/VEGF2 inhibitor cabozantinib by the end of the year, but as that project winds down, plans for a suite of new indications are in the works as the company tries to leverage its asset as fully as possible.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet